Latest News from "The Pink Sheet" DAILY

Celgene's Revlimid Thrives As First-Line Multiple Myeloma Treatment

Spurred by backing of physician opinion leaders, sales grow quickly ahead of first-line filing, which is expected in the second half of 2010.   read more

 

BMS, Lilly Reach Agreement To Co-Develop Erbitux Follow-On

During its fourth-quarter 2009 earnings call, Bristol also urged investors to show patience with disappointing sales of Onglyza.   read more

 

Seoul Court Maintains Stance Not To Raise Novartis' Glivec Price; Health Ministry May Appeal To Higher Court

A mandated price cut for imatinib goes against ?fairness? and the purpose of the EU free trade agreement, the court said.   read more

 

AstraZeneca Reports Higher Profits, But Cuts R&D Jobs

AstraZeneca's patent expiry woes clear amid disappointing '09 results.   read more

 

Amgen Taps GSK's Stiefel Unit To Promote Enbrel To Dermatologists

Deal will aid Amgen's promotional efforts around Enbrel in psoriasis as the entrenched biologic faces down Humira, Stelara in the market.   read more

 

Rep. Waxman Will Support Targeted Document Requests On White House Health Reform Deals

House committee considers Republican resolution seeking extensive documentation from the administration regarding deal by PhRMA and other industry groups relating to health care reform legislation.   read more

 

"The Pink Sheet" DAILY - Daily, in-depth analysis of the key developments shaping the biopharma industry. Not a subscriber? To register for a free trial, click here